New York, the U.S.A-based leading provider of biospecimens, research models and services, BioIVT acquired Fidelis Research. The company announced the acquisition on September 26, 2022. However, it did not disclose the financial details pertaining to the purchase.
Purpose of acquisition by BioIVT
With the latest purchase of Fidelis Research, BioIVT can now increase its global network for collecting high-quality, disease-state biospecimens.
It also allows the company to extend its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.
Meanwhile, the biotech company intends to expand its support of precision medicine research in multiple therapeutic areas.
What the officials of BioIVT have to say
Dr Richard Haigh, BioIVT Chief Executive Officer (CEO), said, “This transaction further increases the scale and depth of BioIVT’s global operations by adding new clinical collection sites, which are predominantly hospital-based, focused on oncology, heme-oncology, and autoimmune cases. We now have an exemplary global footprint for the collection and provision of high-quality, fully annotated disease-state biospecimens in Europe, Asia, and the US. Through Fidelis Research, we deepen our presence in Europe. We can provide our clients with a broad array of fresh, clinically collected, disease-state tissues and biofluids, and expanded cell products globally.”
Shannon Richey, Vice President at BioIVT, further added, “We are delighted that the entire Fidelis Research team is joining BioIVT. BioIVT and Fidelis share a commitment to collect biospecimens to exacting standards, ensuring our clients receive high quality, fit-for-purpose biospecimens, so they can reach their R&D goals and develop safe and effective new medicines faster,” said. I am especially excited to add biospecimens collected through the Fidelis network to our NGS annotation program.”
What the CEO of Fidelis Research has to say
Veselin Stefanov, CEO at Fidelis Research, said, “We at Fidelis Research are excited to join BioIVT and become part of a global team that shares our high standards of client service and biospecimen collection quality, ethics, and regulatory compliance. We look forward to being able to offer our clients access to BioIVT’s global biospecimen network and an even more comprehensive portfolio of research products and services. We are grateful to our investors, Empower Capital and Integrity Capital for their trust, support, and guidance throughout the years, which have enabled us to start this new chapter of our business at BioIVT.”
About BioIVT
Jeffrey Gatz launched the company in 1981. The company operates as a leading global provider of research models and value-added research services for drug discovery and development. It specializes in control and disease-state biospecimens, such as human and animal tissues, cell products, blood and other biofluids.
For more extensive analysis and Market Intelligence reports, feel free to approach us.
We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know
if there are any discrepancies in any of our published stories,
-how we can improve,
-what stories you would like us to cover
–what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!
Next Article
